Dr. Greg Aune was born in Eastern Washington State and grew up on a wheat farm. At age 16, he was diagnosed with Hodgkin’s Lymphoma and was successfully cured of his disease after undergoing one year of chemotherapy and radiation treatments. His cancer experience led Dr. Aune down a path to becoming a pediatric oncologist and physician scientist.
He attended Pacific Lutheran University in Tacoma, Washington, where he graduated Summa Cum Laude with separate degrees in chemistry and biology. From there he moved to Texas and pursued training in both medicine and basic science.
In 2001, he moved to the Washington D.C. area with his wife and continued graduate work at the National Cancer Institute (NCI), under the supervision of Yves Pommier, M.D., Ph.D., director of the Laboratory of Molecular Pharmacology. Throughout the next four years, Dr. Aune continued educational activities at the University of Texas-Houston and MD Anderson Cancer Center, while conducting his research at NCI. In 2005, he graduated from the University of Texas-Houston with an M.D. and Ph.D. in the field of tumor biology and experimental therapeutics. The focus of Dr. Aune’s Ph.D. dissertation was the molecular mechanism of cytotoxicity of the novel DNA minor groove alkylator, Ecteinascidin 743. Dr. Aune completed his pediatrics residency at Johns Hopkins Hospital in Baltimore, M.D. in 2008 and subspecialty training in hematology-oncology in 2010 here at the University of Texas Health Science Center San Antonio.
During the beginning months of his hematology-oncology fellowship, Dr. Aune underwent open heart surgery to replace his aortic valve and bypass three blocked coronary arteries – the direct result of chemotherapy and radiation he had received 20 years prior. Similar to his teenage battle with cancer, this personal struggle guided his academic path towards developing a laboratory program investigating the basic science of pediatric cancer survivorship. He is the first graduate of the Pediatric hematology-oncology fellowship supported generously by Mr. Bill Greehey and Greehey CCRI.
Dr. Aune is board certified in both general pediatrics and hematology-oncology and maintains membership and actively participates in numerous national organizations devoted to childhood cancer research and cancer survivorship.
Andrews TG, Lindsey ML, Lange RA, Aune GJ. Cardiac Assessment in Pediatric Mice: Strain Analysis as a Diagnostic Measurement. Echocardiography. 2013 Sep 19. doi: 10.1111/echo.12351. [Epub ahead of print]
Patterson NL, Iyer RP, Bras LD, Li Y, Andrews TG, Aune GJ, Lange RA, Lindsey ML. Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl. 2013 Mar 27.
doi: 10.1002/prca.201200100. [Epub ahead of print]
Policarpio-Nicolas ML, Valente PT, Aune GJ, Higgins RA. Isolated vaginal myeloid sarcoma in a 16-year-old girl. Ann Diagn Pathol. 2011 Jun 7.
Aune GJ, Kazutaka T, Sordet O, Guirouilh-Barbat J, Antony S, Bohr W, and Pommier Y. Von Hippel-Lindau and Transcription-coupled Nucleotide Excision Repair Dependent Degradation of RNA Polymerase II in Response to Trabectedin. Clinical Cancer Research. 2008 Oct 15;14(20):6449-55.
Aune, GJ. Fluids and Electrolytes. Harriet Lane Handbook. pp. 301-326.
Aune, GJ. Wilms Tumor. Pediatrics in Review. 2008 April. 29(4):142-3.
Furuta T, Hayward RL, Meng LH, Takemura H, Aune GJ, Bommer WM, Aladjem, Kohn KW, and Pommier Y. p21CKDN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene. 2006 May 11; 25 (20). 2839-49.
Furuta T, Takemura H, Liao Z, Aune GJ, Redon C, Sedelnikova O, Pilch D, Rogaku E, Celeste A, Tang Chen H, Nussenzweig A, Aladjem M, Bonner W, and Pommier Y. Phosphorylation of Histone H2AX and activation of Mre11, Rad50, and Nbs1 in Response to Replication-Dependent DNA-Double-strand Breaks Induced by Mammalian DNA Topoisomerase I cleavage complexes. J Biol Chem. 2003 May 30;278(22):20303-12.
Furuta T, Ueda T, Aune GJ, Sarasin A, Kraemer KH, and Pommier Y. Transcription Coupled-Nucleotide Excision Repair as a Determinant of Cisplatin Sensitivity of Human Cells. Cancer Res 2002 Sep 1;62(17):4899-90.
Aune GJ, Furuta T, and Pommier Y. Ecteinascidin 743: A novel anticancer drug with a unique mechanism of action. Anti-Cancer Drugs 2002; 13: 1-12.